Ireland - English - HPRA (Health Products Regulatory Authority)

bristol laboratories limited - trazodone hydrochloride - capsule, hard - 100 milligram(s) - other antidepressants; trazodone

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 114.3 mg (equivalent: atomoxetine, qty 114.3 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 91.44 mg (equivalent: atomoxetine, qty 91.44 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 68.58 mg (equivalent: atomoxetine, qty 68.58 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 45.72 mg (equivalent: atomoxetine, qty 40 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 28.58 mg (equivalent: atomoxetine, qty 25 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 20.57 mg (equivalent: atomoxetine, qty 18 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; maize starch; pregelatinised maize starch; titanium dioxide; iron oxide yellow; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 11.43 mg (equivalent: atomoxetine, qty 10 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - ziprasidone hydrochloride, quantity: 43.44 mg (equivalent: ziprasidone, qty 40 mg) - capsule, hard - excipient ingredients: titanium dioxide; pregelatinised maize starch; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; gelatin; indigo carmine - for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy;,as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - ziprasidone hydrochloride, quantity: 86.88 mg (equivalent: ziprasidone, qty 80 mg) - capsule, hard - excipient ingredients: magnesium stearate; croscarmellose sodium; gelatin; indigo carmine; pregelatinised maize starch; colloidal anhydrous silica; titanium dioxide - for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy;,as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.